Literature DB >> 33452107

PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques.

Keith D Kauffman1, Shunsuke Sakai1, Nickiana E Lora1, Sivaranjani Namasivayam2, Paul J Baker3, Olena Kamenyeva4, Taylor W Foreman1, Christine E Nelson1, Deivide Oliveira-de-Souza5, Caian L Vinhaes5, Ziv Yaniv6, Cecilia S Lindestam Arleham7, Alessandro Sette7,8, Gordon J Freeman9, Rashida Moore10, Alan Sher2, Katrin D Mayer-Barber3, Bruno B Andrade5, Juraj Kabat4, Laura E Via11, Daniel L Barber12.   

Abstract

Boosting immune cell function by targeting the coinhibitory receptor PD-1 may have applications in the treatment of chronic infections. Here, we examine the role of PD-1 during Mycobacterium tuberculosis (Mtb) infection of rhesus macaques. Animals treated with anti-PD-1 monoclonal antibody developed worse disease and higher granuloma bacterial loads compared with isotype control-treated monkeys. PD-1 blockade increased the number and functionality of granuloma Mtb-specific CD8 T cells. In contrast, Mtb-specific CD4 T cells in anti-PD-1-treated macaques were not increased in number or function in granulomas, expressed increased levels of CTLA-4, and exhibited reduced intralesional trafficking in live imaging studies. In granulomas of anti-PD-1-treated animals, multiple proinflammatory cytokines were elevated, and more cytokines correlated with bacterial loads, leading to the identification of a role for caspase 1 in the exacerbation of tuberculosis after PD-1 blockade. Last, increased Mtb bacterial loads after PD-1 blockade were found to associate with the composition of the intestinal microbiota before infection in individual macaques. Therefore, PD-1-mediated coinhibition is required for control of Mtb infection in macaques, perhaps because of its role in dampening detrimental inflammation and allowing for normal CD4 T cell responses.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33452107      PMCID: PMC8300572          DOI: 10.1126/sciimmunol.abf3861

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  58 in total

1.  Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.

Authors:  David M Dorfman; Julia A Brown; Aliakbar Shahsafaei; Gordon J Freeman
Journal:  Am J Surg Pathol       Date:  2006-07       Impact factor: 6.394

2.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

3.  A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets.

Authors:  Laura E Via; Kathleen England; Danielle M Weiner; Daniel Schimel; Matthew D Zimmerman; Emmanuel Dayao; Ray Y Chen; Lori E Dodd; Mike Richardson; Katherine K Robbins; Ying Cai; Dima Hammoud; Peter Herscovitch; Véronique Dartois; JoAnne L Flynn; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

4.  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Authors:  V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

5.  Defective positioning in granulomas but not lung-homing limits CD4 T-cell interactions with Mycobacterium tuberculosis-infected macrophages in rhesus macaques.

Authors:  K D Kauffman; M A Sallin; S Sakai; O Kamenyeva; J Kabat; D Weiner; M Sutphin; D Schimel; L Via; C E Barry; T Wilder-Kofie; I Moore; R Moore; D L Barber
Journal:  Mucosal Immunol       Date:  2017-07-26       Impact factor: 7.313

6.  Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.

Authors:  Sivaranjani Namasivayam; Mamoudou Maiga; Wuxing Yuan; Vishal Thovarai; Diego L Costa; Lara R Mittereder; Matthew F Wipperman; Michael S Glickman; Amiran Dzutsev; Giorgio Trinchieri; Alan Sher
Journal:  Microbiome       Date:  2017-07-07       Impact factor: 14.650

Review 7.  Host-directed therapies for bacterial and viral infections.

Authors:  Stefan H E Kaufmann; Anca Dorhoi; Richard S Hotchkiss; Ralf Bartenschlager
Journal:  Nat Rev Drug Discov       Date:  2017-09-22       Impact factor: 84.694

8.  Enhancing SIV-specific immunity in vivo by PD-1 blockade.

Authors:  Vijayakumar Velu; Kehmia Titanji; Baogong Zhu; Sajid Husain; Annette Pladevega; Lilin Lai; Thomas H Vanderford; Lakshmi Chennareddi; Guido Silvestri; Gordon J Freeman; Rafi Ahmed; Rama Rao Amara
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

9.  Mycobacterium tuberculosis exploits human interferon γ to stimulate macrophage extracellular trap formation and necrosis.

Authors:  Ka-Wing Wong; Williams R Jacobs
Journal:  J Infect Dis       Date:  2013-03-08       Impact factor: 5.226

10.  Development of Mycobacterium avium Complex Lung Disease in Patients With Lung Cancer on Immune Checkpoint Inhibitors.

Authors:  Kohei Fujita; Yuki Yamamoto; Osamu Kanai; Misato Okamura; Koichi Nakatani; Tadashi Mio
Journal:  Open Forum Infect Dis       Date:  2020-03-07       Impact factor: 3.835

View more
  17 in total

Review 1.  Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review.

Authors:  Andrea Gramegna; Andrea Lombardi; Nicola I Lorè; Francesco Amati; Ivan Barone; Cecilia Azzarà; Daniela Cirillo; Stefano Aliberti; Andrea Gori; Francesco Blasi
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

2.  A non-canonical type 2 immune response coordinates tuberculous granuloma formation and epithelialization.

Authors:  Mark R Cronan; Erika J Hughes; W Jared Brewer; Gopinath Viswanathan; Emily G Hunt; Bindu Singh; Smriti Mehra; Stefan H Oehlers; Simon G Gregory; Deepak Kaushal; David M Tobin
Journal:  Cell       Date:  2021-03-23       Impact factor: 41.582

3.  Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease.

Authors:  Gabriele Pollara; Carolin T Turner; Joshua Rosenheim; Aneesh Chandran; Lucy C K Bell; Ayesha Khan; Amit Patel; Luis Felipe Peralta; Anna Folino; Ayse Akarca; Cristina Venturini; Tina Baker; Simone Ecker; Fabio L M Ricciardolo; Teresa Marafioti; Cesar Ugarte-Gil; David A J Moore; Benjamin M Chain; Gillian S Tomlinson; Mahdad Noursadeghi
Journal:  Sci Transl Med       Date:  2021-05-05       Impact factor: 17.956

4.  Tissue-resident-like CD4+ T cells secreting IL-17 control Mycobacterium tuberculosis in the human lung.

Authors:  Paul Ogongo; Liku B Tezera; Amanda Ardain; Shepherd Nhamoyebonde; Duran Ramsuran; Alveera Singh; Abigail Ng'oepe; Farina Karim; Taryn Naidoo; Khadija Khan; Kaylesh J Dullabh; Michael Fehlings; Boon Heng Lee; Alessandra Nardin; Cecilia S Lindestam Arlehamn; Alessandro Sette; Samuel M Behar; Adrie Jc Steyn; Rajhmun Madansein; Henrik N Kløverpris; Paul T Elkington; Alasdair Leslie
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 19.456

Review 5.  Understanding the tuberculosis granuloma: the matrix revolutions.

Authors:  Paul Elkington; Marta E Polak; Michaela T Reichmann; Alasdair Leslie
Journal:  Trends Mol Med       Date:  2021-12-15       Impact factor: 11.951

Review 6.  Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics.

Authors:  Ana B Enriquez; Angelo Izzo; Shannon M Miller; Erica L Stewart; Robert N Mahon; Daniel J Frank; Jay T Evans; Jyothi Rengarajan; James A Triccas
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 8.786

7.  Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child.

Authors:  Silvia Vilarinho; Richard P Lifton; Bertrand Boisson; Laurent Abel; Dusan Bogunovic; Nico Marr; Luigi D Notarangelo; Stuart G Tangye; Tasuku Honjo; Philippe Gros; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Masato Ogishi; Rui Yang; Caner Aytekin; David Langlais; Mathieu Bourgey; Taushif Khan; Fatima Al Ali; Mahbuba Rahman; Ottavia M Delmonte; Maya Chrabieh; Peng Zhang; Conor Gruber; Simon J Pelham; András N Spaan; Jérémie Rosain; Wei-Te Lei; Scott Drutman; Matthew D Hellmann; Margaret K Callahan; Matthew Adamow; Phillip Wong; Jedd D Wolchok; Geetha Rao; Cindy S Ma; Yuka Nakajima; Tomonori Yaguchi; Kenji Chamoto; Samuel C Williams; Jean-Francois Emile; Flore Rozenberg; Michael S Glickman; Franck Rapaport; Gaspard Kerner; Garrett Allington; Ilhan Tezcan; Deniz Cagdas; Ferda O Hosnut; Figen Dogu; Aydan Ikinciogullari; V Koneti Rao; Leena Kainulainen; Vivien Béziat; Jacinta Bustamante
Journal:  Nat Med       Date:  2021-06-28       Impact factor: 53.440

Review 8.  Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases.

Authors:  Hiroto Nakano; Takuto Miyamoto; Yelena Y Janjigian; Sohtaro Mine; Hiroaki Mitsuya; Naoto T Ueno; Elad Sharon; Shunsuke Sakai; William C Timmer; Shuichiro Nakabo; Tomoko Ikeuchi; Saori Fujiwara; Minori Kinjo; Tadashi Inuzuka; Hayato Kume; Keisuke Shirai; Norihiro Yamaguchi; Kazuaki Takabe; Naoko Takebe
Journal:  World J Oncol       Date:  2021-12-13

Review 9.  Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy.

Authors:  Tommaso Morelli; Kohei Fujita; Gil Redelman-Sidi; Paul T Elkington
Journal:  Thorax       Date:  2021-10-04       Impact factor: 9.139

10.  Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues.

Authors:  Christine E Nelson; Sivaranjani Namasivayam; Taylor W Foreman; Keith D Kauffman; Shunsuke Sakai; Danielle E Dorosky; Nickiana E Lora; Kelsie Brooks; E Lake Potter; Nicole L Garza; Bernard A P Lafont; Reed F Johnson; Mario Roederer; Alan Sher; Daniela Weiskopf; Alessandro Sette; Emmie de Wit; Heather D Hickman; Jason M Brenchley; Laura E Via; Daniel L Barber; Ayan Abdi; Emmuanual K Dayao; Joel D Fleegle; Felipe Gomez; Michaela K Piazza; Katelyn M Repoli; Becky Y Sloan; Ashley L Butler; April M Walker; Danielle M Weiner; Michael J Woodcock; Alexandra Vatthauer
Journal:  Sci Immunol       Date:  2022-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.